PRKACA: the catalytic subunit of protein kinase A and adrenocortical tumors

Area of Science:

• Endocrinology
• Molecular Biology
• Oncology

Background:

• Cyclic-AMP (cAMP)-dependent protein kinase (PKA) is central to cellular signaling.
• Inactivating mutations in PRKAR1A cause Carney complex and primary pigmented nodular adrenocortical disease (PPNAD).
• PKA dysregulation is linked to ACTH-independent Cushing syndrome (AICS) and other adrenocortical conditions.

Purpose of the Study:

• To review the role of PRKACA mutations in adrenocortical tumorigenesis.
• To summarize PKA's involvement in adrenocortical lesions.
• To discuss potential therapeutic targets within the PRKACA and PKA pathway.

Main Methods:

• Literature review of genetic mutations and their functional consequences.
• Analysis of in vitro studies on PRKACA mutations.
• Synthesis of current understanding of PKA pathway in adrenocortical diseases.

Main Results:

• PRKAR1A mutations are associated with Carney complex, PPNAD, and AICS.
• PRKACA mutations, including germline copy number gain and somatic Leu206Arg, are implicated in cortisol-producing bilateral adrenocortical hyperplasias and adenomas.
• The somatic PRKACA mutation results in constitutive catalytic subunit activity, independent of regulatory subunits.

Conclusions:

• PRKACA plays a significant role in the development of adrenocortical tumors.
• Understanding PKA pathway dysregulation is crucial for diagnosing and treating adrenocortical pathologies.
• Targeting PRKACA and the PKA pathway holds promise for novel therapeutic interventions.